AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

NICE backs funding for AZ's Lynparza ovarian cancer maintena...

NICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages of the disease as a maintenance treatment after an initial round o

AZ says recovery to continue to despite patent expiry and Br...

AstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will offset a major patent expiry and the impact of Brexit.

Relief for GSK as Tesaro’s Zejula hits the mark in ovarian c...

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type of metastatic ovarian cancer.

Merck and Pfizer stop third Bavencio ovarian cancer trial

Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno